Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation

Nature Communications

Volumn 6, Issue , 2015, Pages

  Papaspyridonos, Marianna ^a,h   Matei, Irina ^a   Huang, Yujie ^a   Do Rosario Andre, Maria ^a,b   Brazier Mitouart, Helene ^a   Waite, Janelle C ^c   Chan, April S ^a   Kalter, Julie ^c   Ramos, Ilyssa ^c   Wu, Qi ^c   Williams, Caitlin ^a   Wolchok, Jedd D ^d   Chapman, Paul B ^d   Peinado, Hector ^a,e   Anandasabapathy, Niroshana ^f   Ocean, Allyson J ^a   Kaplan, Rosandra N ^g   Greenfield, Jeffrey P ^a   Bromberg, Jacqueline ^d   Skokos, Dimitris ^c   Lyden, David ^a,d   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Centro Nacional de Investigaciones Oncológicas   (Spain)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; INHIBITOR OF DIFFERENTIATION 1; INTERLEUKIN 6; LENTIVIRUS VECTOR; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR;

BLOOD; CANCER; CELL ORGANELLE; GENE EXPRESSION; IMMUNE RESPONSE; MATURATION; PLASMA; TUMOR;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BONE MARROW CELL; BREAST ADENOCARCINOMA; BREAST METASTASIS; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; METASTATIC MELANOMA; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY TUMOR; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; STEADY STATE; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE COURSE; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; METASTASIS; MONONUCLEAR CELL; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; CELL DIFFERENTIATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INTERFERON REGULATORY FACTORS; LEUKOCYTES, MONONUCLEAR; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASM METASTASIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84928884360     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7840     Document Type: Article

References (70)

1. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268 (2012).
2. Peinado, H., Lavotshkin, S. & Lyden, D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 21, 139-146 (2011).
3. Serafini, P., Borrello, I. & Bronte, V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53-65 (2006).
4. Fricke, I. et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13, 4840-4848 (2007).
5. Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911-920 (2007).
6. Della Bella, S. et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89, 1463-1472 (2003).
7. Almand, B. et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766 (2000).
8. Bronte, V., Serafini, P., Apolloni, E. & Zanovello, P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24, 431-446 (2001).
9. Talmadge, J. E. & Gabrilovich, D. I. History of myeloid-derived suppressor cells. Nat. Rev. 13, 739-752 (2013).
10. Steinman, R. M. & Banchereau, J. Taking dendritic cells into medicine. Nature 449, 419-426 (2007).
11. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
12. Pages, F. et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093-1102 (2010).
13. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
14. Rodriguez, P. C. & Ochoa, A. C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180-191 (2008).
15. Sica, A. & Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155-1166 (2007).
16. Kusmartsev, S. et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 181, 346-353 (2008).
17. Kusmartsev, S., Nefedova, Y., Yoder, D. & Gabrilovich, D. I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989-999 (2004).
18. Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802 (2008).
19. Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689 (2001).
20. Zea, A. H. et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044-3048 (2005).
21. Mandruzzato, S. et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182, 6562-6568 (2009).
22. Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L. & Weintraub, H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61, 49-59 (1990).
23. Chan, A. S. et al. Id1 represses osteoclast-dependent transcription and affects bone formation and hematopoiesis. PLoS ONE 4, e7955 (2009).
24. Fong, S., Debs, R. J. & Desprez, P. Y. Id genes and proteins as promising targets in cancer therapy. Trends Mol. Med. 10, 387-392 (2004).
25. Perk, J., Iavarone, A. & Benezra, R. Id family of helix-loop-helix proteins in cancer. Nat. Rev. 5, 603-614 (2005).
26. Lyden, D. et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401, 670-677 (1999).
27. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201 (2001).
28. Gao, D. et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319, 195-198 (2008).
29. Buitenhuis, M. et al. Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors Id1 and Id2. Blood 105, 4272-4281 (2005).
30. Geest, C. R., Buitenhuis, M., Vellenga, E. & Coffer, P. J. Ectopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia. Haematologica 94, 1075-1084 (2009).
31. Jankovic, V. et al. Id1 restrains myeloid commitment, maintaining the selfrenewal capacity of hematopoietic stem cells. Proc. Natl Acad. Sci. USA 104, 1260-1265 (2007).
32. Suh, H. C. et al. Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene 27, 5612-5623 (2008).
33. Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
34. Sinha, P. et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181, 4666-4675 (2008).
35. Hiratsuka, S. et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 10, 1349-1355 (2008).
36. Serafini, P., Mgebroff, S., Noonan, K. & Borrello, I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68, 5439-5449 (2008).
37. MacDonald, K. P. et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J. Immunol. 174, 1841-1850 (2005).
38. Lu, T. & Gabrilovich, D. I. Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin. Cancer Res. 18, 4877-4882 (2012).
39. Chambers, R. C., Leoni, P., Kaminski, N., Laurent, G. J. & Heller, R. A. Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am. J. Pathol. 162, 533-546 (2003).
40. David, L., Mallet, C., Mazerbourg, S., Feige, J. J. & Bailly, S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109, 1953-1961 (2007).
41. Liang, Y. Y., Brunicardi, F. C. & Lin, X. Smad3 mediates immediate early induction of Id1 by TGF-beta. Cell Res. 19, 140-148 (2009).
42. Strong, N., Millena, A. C., Walker, L., Chaudhary, J. & Khan, S. A. Inhibitor of differentiation 1 (Id1) and Id3 proteins play different roles in TGFbeta effects on cell proliferation and migration in prostate cancer cells. Prostate 73, 624-633 (2012).
43. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883-891 (2012).
44. Waight, J. D. et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J. Clin. Invest. 123, 4464-4478 (2013).
45. Schonheit, J. et al. PU.1 level-directed chromatin structure remodeling at the Irf8 gene drives dendritic cell commitment. Cell Rep. 3, 1617-1628 (2013).
46. Kusmartsev, S. et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14, 8270-8278 (2008).
47. Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59 (2009).
48. Vuk-Pavlovic, S. et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 70, 443-455 (2010).
49. Filipazzi, P. et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocytemacrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25, 2546-2553 (2007).
50. Ruzinova, M. B. & Benezra, R. Id proteins in development, cell cycle and cancer. Trends Cell. Biol. 13, 410-418 (2003).
51. O'Brien, C. A. et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 21, 777-792 (2012).
52. Arteaga, C. L. Inhibition of TGFbeta signaling in cancer therapy. Curr. Opin. Genet. Dev. 16, 30-37 (2006).
53. Sonda, N., Chioda, M., Zilio, S., Simonato, F. & Bronte, V. Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr. Opin. Immunol. 23, 279-285 (2011).
54. Anido, J. et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655-668 (2010).
55. Challen, G. A., Boles, N. C., Chambers, S. M. & Goodell, M. A. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 6, 265-278 (2010).
56. Kang, Y., Chen, C. R. & Massague, J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol. Cell 11, 915-926 (2003).
57. Cheng, P. et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249 (2008).
58. Laxmanan, S. et al. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem. Biophys. Res. Commun. 334, 193-198 (2005).
59. Youn, J. I. et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat. Immunol. 14, 211-220 (2013).
60. Hambleton, S. et al. IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl. J. Med. 365, 127-138 (2011).
61. Becker, A. M. et al. IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors. Blood 119, 2003-2012 (2012).
62. Stewart, T. J. et al. Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells. J. Cell. Mol. Med. 13, 3939-3950 (2009).
63. Corzo, C. A. et al. Mechanism regulating reactive oxygen species in tumorinduced myeloid-derived suppressor cells. J. Immunol. 182, 5693-5701 (2009).
64. Huang, B. et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-1131 (2006).
65. Pan, P. Y. et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 70, 99-108 (2010).
66. Ramirez-Montagut, T., Turk, M. J., Wolchok, J. D., Guevara-Patino, J. A. & Houghton, A. N. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22, 3180-3187 (2003).
67. Rosenberg, S. A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat. Rev. Clin. Oncol. 8, 577-585 (2011).
68. Klebanoff, C. A., Acquavella, N., Yu, Z. & Restifo, N. P. Therapeutic cancer vaccines: are we there yet? Immunol. Rev. 239, 27-44 (2011).
69. Umansky, V. & Sevko, A. Melanoma-induced immunosuppression and its neutralization. Semin. Cancer Biol. 22, 319-326 (2012).
70. MacKie, R. M., Hauschild, A. & Eggermont, A. M. Epidemiology of invasive cutaneous melanoma. Ann. Oncol. 20 Suppl 6, vi1-vi7 (2009).